Doximity, Inc.

NYSE:DOCS Voorraadrapport

Marktkapitalisatie: US$7.9b

Doximity Toekomstige groei

Future criteriumcontroles 1/6

Doximity is forecast to grow earnings and revenue by 5.9% and 7.8% per annum respectively. EPS is expected to grow by 9% per annum. Return on equity is forecast to be 19.3% in 3 years.

Belangrijke informatie

5.9%

Groei van de winst

9.0%

Groei van de winst per aandeel

Healthcare Services winstgroei30.6%
Inkomstengroei7.8%
Toekomstig rendement op eigen vermogen19.3%
Dekking van analisten

Good

Laatst bijgewerkt30 Oct 2024

Recente toekomstige groei-updates

Recent updates

Does This Valuation Of Doximity, Inc. (NYSE:DOCS) Imply Investors Are Overpaying?

Nov 02
Does This Valuation Of Doximity, Inc. (NYSE:DOCS) Imply Investors Are Overpaying?

Is Doximity, Inc. (NYSE:DOCS) Potentially Undervalued?

Oct 15
Is Doximity, Inc. (NYSE:DOCS) Potentially Undervalued?

Doximity: Downgrade To Hold On Valuation Concerns

Oct 03

Here's Why Doximity (NYSE:DOCS) Has Caught The Eye Of Investors

Sep 23
Here's Why Doximity (NYSE:DOCS) Has Caught The Eye Of Investors

There's Reason For Concern Over Doximity, Inc.'s (NYSE:DOCS) Massive 27% Price Jump

Aug 18
There's Reason For Concern Over Doximity, Inc.'s (NYSE:DOCS) Massive 27% Price Jump

Doximity (NYSE:DOCS) Looks To Prolong Its Impressive Returns

Aug 10
Doximity (NYSE:DOCS) Looks To Prolong Its Impressive Returns

Doximity Faces Slower Revenue Growth As R&D Costs May Rise

Jul 23

Is Doximity, Inc. (NYSE:DOCS) Trading At A 23% Discount?

Jul 23
Is Doximity, Inc. (NYSE:DOCS) Trading At A 23% Discount?

At US$27.97, Is It Time To Put Doximity, Inc. (NYSE:DOCS) On Your Watch List?

Jul 01
At US$27.97, Is It Time To Put Doximity, Inc. (NYSE:DOCS) On Your Watch List?

Optimistic Investors Push Doximity, Inc. (NYSE:DOCS) Shares Up 26% But Growth Is Lacking

Jun 09
Optimistic Investors Push Doximity, Inc. (NYSE:DOCS) Shares Up 26% But Growth Is Lacking

Doximity Earnings: Better Than Expected, But Still Mixed Outlook (Rating Upgrade)

May 17

Capital Allocation Trends At Doximity (NYSE:DOCS) Aren't Ideal

May 04
Capital Allocation Trends At Doximity (NYSE:DOCS) Aren't Ideal

Doximity: Significant Upside Remains, But Not Until The Growth Story Returns

Apr 29

With Doximity, Inc. (NYSE:DOCS) It Looks Like You'll Get What You Pay For

Apr 16
With Doximity, Inc. (NYSE:DOCS) It Looks Like You'll Get What You Pay For

Estimating The Fair Value Of Doximity, Inc. (NYSE:DOCS)

Mar 26
Estimating The Fair Value Of Doximity, Inc. (NYSE:DOCS)

Doximity: Rating Upgrade To Buy As Outlook Turns Positive

Feb 21

We Like Doximity's (NYSE:DOCS) Earnings For More Than Just Statutory Profit

Feb 15
We Like Doximity's (NYSE:DOCS) Earnings For More Than Just Statutory Profit

What Is Doximity, Inc.'s (NYSE:DOCS) Share Price Doing?

Feb 13
What Is Doximity, Inc.'s (NYSE:DOCS) Share Price Doing?

Doximity: Downside Is Contained, While Upside Depends On Management's Game Plan

Jan 16

Doximity (NYSE:DOCS) May Have Issues Allocating Its Capital

Jan 04
Doximity (NYSE:DOCS) May Have Issues Allocating Its Capital

Doximity, Inc.'s (NYSE:DOCS) Intrinsic Value Is Potentially 29% Above Its Share Price

Dec 14
Doximity, Inc.'s (NYSE:DOCS) Intrinsic Value Is Potentially 29% Above Its Share Price

Doximity Earnings: Steer Clear Of This Rollercoaster War Of Optimism Vs. Skepticism

Nov 10

Doximity: Adding Value Using AI But Faces Near-Term Risks

Nov 01

Is Doximity, Inc. (NYSE:DOCS) Potentially Undervalued?

Oct 30
Is Doximity, Inc. (NYSE:DOCS) Potentially Undervalued?

Doximity (NYSE:DOCS) Might Be Having Difficulty Using Its Capital Effectively

Sep 25
Doximity (NYSE:DOCS) Might Be Having Difficulty Using Its Capital Effectively

Doximity: Rating Downgrade As Investors Shift Focus To The Near-Term Outlook

Aug 24

Doximity Earnings: Too Many Problems, Sell

Aug 09

A Look At The Intrinsic Value Of Doximity, Inc. (NYSE:DOCS)

Jul 29
A Look At The Intrinsic Value Of Doximity, Inc. (NYSE:DOCS)

Why Doximity, Inc. (NYSE:DOCS) Could Be Worth Watching

Jul 09
Why Doximity, Inc. (NYSE:DOCS) Could Be Worth Watching

Doximity: Continue To See Positive Upside From Current Stock Level

Jul 05

The Returns At Doximity (NYSE:DOCS) Aren't Growing

Jun 21
The Returns At Doximity (NYSE:DOCS) Aren't Growing

Doximity: Digital Health Play With Strong Fundamentals

Jun 21

A Look At The Fair Value Of Doximity, Inc. (NYSE:DOCS)

Apr 07
A Look At The Fair Value Of Doximity, Inc. (NYSE:DOCS)

Doximity (NYSE:DOCS) Is Reinvesting At Lower Rates Of Return

Mar 20
Doximity (NYSE:DOCS) Is Reinvesting At Lower Rates Of Return

Doximity: Good Business But Extremely Overvalued

Feb 18

Doximity Q3 Earnings: Disappointing Results

Feb 10

Calculating The Fair Value Of Doximity, Inc. (NYSE:DOCS)

Dec 25
Calculating The Fair Value Of Doximity, Inc. (NYSE:DOCS)

Doximity: On The Right Path To Further Consolidate Market Share

Dec 22

Here's What's Concerning About Doximity's (NYSE:DOCS) Returns On Capital

Dec 04
Here's What's Concerning About Doximity's (NYSE:DOCS) Returns On Capital

Winst- en omzetgroeiprognoses

NYSE:DOCS - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
3/31/202761318723925010
3/31/202656516123223716
3/31/202552014720521616
6/30/2024494161162168N/A
3/31/2024475148178184N/A
12/31/2023468138162167N/A
9/30/2023448123160165N/A
6/30/2023437119186192N/A
3/31/2023419113173180N/A
12/31/2022402119173180N/A
9/30/2022384141151159N/A
6/30/2022362148131138N/A
3/31/2022344133121127N/A
12/31/2021317107113117N/A
9/30/202127757110114N/A
6/30/202124330103107N/A
3/31/2021207227883N/A
12/31/2020177144853N/A
3/31/2020116112226N/A
3/31/20198611415N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: DOCS's forecast earnings growth (5.9% per year) is above the savings rate (2.5%).

Winst versus markt: DOCS's earnings (5.9% per year) are forecast to grow slower than the US market (15.4% per year).

Hoge groeiwinsten: DOCS's earnings are forecast to grow, but not significantly.

Omzet versus markt: DOCS's revenue (7.8% per year) is forecast to grow slower than the US market (8.9% per year).

Hoge groei-inkomsten: DOCS's revenue (7.8% per year) is forecast to grow slower than 20% per year.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: DOCS's Return on Equity is forecast to be low in 3 years time (19.3%).

Ontdek groeibedrijven

7D

1Y

7D

1Y

7D

1Y